Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Additional file 3: Table S3. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates reports of improvements meeting or exceeding clinically meaningful and normative values in bot...

Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

EULAR response by study visit (ITT population). Abbreviations: EULAR European League Against Rheumat...

Additional file 3: Figure S2. of Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Gerd Horneff (3415988)
Ariane Klein (3415976)
Jens Klotsche (93841)
Kirsten Minden (3415979)
Hans-Iko Huppertz (344746)
Frank Weller-Heinemann (3415991)
Jasmin Kuemmerle-Deschner (3415985)
Johannes-Peter Haas (2868563)
Anton Hospach (3415982)

November 2016

Drug survival during treatment with etanercept, adalimumab or tocilizumab (combined cohorts) dependi...

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 4: Figure S1. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Numbers needed to treat for ACR 20/50/70 (a), Disease Activity Score based on C reactive protein and...

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modif...

Additional file 9: of Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Jürgen Wollenhaupt (5079800)
Eun-Bong Lee (6561695)
Jeffrey Curtis (3442916)
Joel Silverfield (6561698)
Ketti Terry (6561701)
Koshika Soma (5276285)
Chris Mojcik (6561704)
Ryan DeMasi (4821099)
Sander Strengholt (3486989)
Kenneth Kwok (177017)
Irina Lazariciu (6561707)
Lisy Wang (3532073)
Stanley Cohen (411535)

April 2019

Figure S5. Remission as defined by CDAI (score ≤ 2.8) (a) and SDAI (score ≤ 3.3) (b) (observed). Bas...

Additional file 3: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Adjusted HR for time to serious infection in patients covered by Medicare (n = 5200). (DOCX 13 kb

Additional file 5: Table S4. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates of reporting normative values for the Health Assessment Questionnaire-Disability Index (HAQ-DI...

Additional file 1: of Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Yoshiya Tanaka (186328)
Kazuteru Wada (6492581)
Yoshinori Takahashi (360065)
Owen Hagino (6492584)
Hubert Hoogstraten (6492587)
Neil Graham (181868)
Hideto Kameda (3399878)

March 2019

Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...

Additional file 2: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Adjusted HR for time to serious infection in patients censored after they stopped/switched their ini...

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Mark Genovese (3442910)
Rene Westhovens (11539)
Luc Meuleners (4996577)
Annegret Van der Aa (4996583)
Pille Harrison (4996580)
Chantal Tasset (4996586)
Arthur Kavanaugh (2683)

March 2018

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...

Additional file 6: of Safety and efficacy of tofacitinib for up to 9.5âyears in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

JĂźrgen Wollenhaupt (6561710)
Eun-Bong Lee (6561695)
Jeffrey Curtis (3442916)
Joel Silverfield (6561698)
Ketti Terry (6561701)
Koshika Soma (5276285)
Chris Mojcik (6561704)
Ryan DeMasi (4821099)
Sander Strengholt (3486989)
Kenneth Kwok (177017)
Irina Lazariciu (6561707)
Lisy Wang (3532073)
Stanley Cohen (411535)

April 2019

Figure S3. Mean (SE) ALT (a), AST (b), hemoglobin (c), and serum creatinine (d) over time. Baseline ...

Additional file 2: of Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Jürgen Wollenhaupt (5079800)
Eun-Bong Lee (6561695)
Jeffrey Curtis (3442916)
Joel Silverfield (6561698)
Ketti Terry (6561701)
Koshika Soma (5276285)
Chris Mojcik (6561704)
Ryan DeMasi (4821099)
Sander Strengholt (3486989)
Kenneth Kwok (177017)
Irina Lazariciu (6561707)
Lisy Wang (3532073)
Stanley Cohen (411535)

April 2019

Figure S1. Patient disposition (a) and discontinuation over time (b). aFour patients in the tofaciti...

Additional file 3: Table S3. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates reports of improvements meeting or exceeding clinically meaningful and normative values in bot...

Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

EULAR response by study visit (ITT population). Abbreviations: EULAR European League Against Rheumat...

Additional file 3: Figure S2. of Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Gerd Horneff (3415988)
Ariane Klein (3415976)
Jens Klotsche (93841)
Kirsten Minden (3415979)
Hans-Iko Huppertz (344746)
Frank Weller-Heinemann (3415991)
Jasmin Kuemmerle-Deschner (3415985)
Johannes-Peter Haas (2868563)
Anton Hospach (3415982)

November 2016

Drug survival during treatment with etanercept, adalimumab or tocilizumab (combined cohorts) dependi...

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 4: Figure S1. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Numbers needed to treat for ACR 20/50/70 (a), Disease Activity Score based on C reactive protein and...

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modif...

Additional file 9: of Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Jürgen Wollenhaupt (5079800)
Eun-Bong Lee (6561695)
Jeffrey Curtis (3442916)
Joel Silverfield (6561698)
Ketti Terry (6561701)
Koshika Soma (5276285)
Chris Mojcik (6561704)
Ryan DeMasi (4821099)
Sander Strengholt (3486989)
Kenneth Kwok (177017)
Irina Lazariciu (6561707)
Lisy Wang (3532073)
Stanley Cohen (411535)

April 2019

Figure S5. Remission as defined by CDAI (score ≤ 2.8) (a) and SDAI (score ≤ 3.3) (b) (observed). Bas...

Additional file 3: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Adjusted HR for time to serious infection in patients covered by Medicare (n = 5200). (DOCX 13 kb

Additional file 5: Table S4. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates of reporting normative values for the Health Assessment Questionnaire-Disability Index (HAQ-DI...

Additional file 1: of Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Yoshiya Tanaka (186328)
Kazuteru Wada (6492581)
Yoshinori Takahashi (360065)
Owen Hagino (6492584)
Hubert Hoogstraten (6492587)
Neil Graham (181868)
Hideto Kameda (3399878)

March 2019

Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...

Additional file 2: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Adjusted HR for time to serious infection in patients censored after they stopped/switched their ini...

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Mark Genovese (3442910)
Rene Westhovens (11539)
Luc Meuleners (4996577)
Annegret Van der Aa (4996583)
Pille Harrison (4996580)
Chantal Tasset (4996586)
Arthur Kavanaugh (2683)

March 2018

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...

Additional file 6: of Safety and efficacy of tofacitinib for up to 9.5âyears in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

JĂźrgen Wollenhaupt (6561710)
Eun-Bong Lee (6561695)
Jeffrey Curtis (3442916)
Joel Silverfield (6561698)
Ketti Terry (6561701)
Koshika Soma (5276285)
Chris Mojcik (6561704)
Ryan DeMasi (4821099)
Sander Strengholt (3486989)
Kenneth Kwok (177017)
Irina Lazariciu (6561707)
Lisy Wang (3532073)
Stanley Cohen (411535)

April 2019

Figure S3. Mean (SE) ALT (a), AST (b), hemoglobin (c), and serum creatinine (d) over time. Baseline ...

Additional file 2: of Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Jürgen Wollenhaupt (5079800)
Eun-Bong Lee (6561695)
Jeffrey Curtis (3442916)
Joel Silverfield (6561698)
Ketti Terry (6561701)
Koshika Soma (5276285)
Chris Mojcik (6561704)
Ryan DeMasi (4821099)
Sander Strengholt (3486989)
Kenneth Kwok (177017)
Irina Lazariciu (6561707)
Lisy Wang (3532073)
Stanley Cohen (411535)

April 2019

Figure S1. Patient disposition (a) and discontinuation over time (b). aFour patients in the tofaciti...

Additional file 3: Table S3. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates reports of improvements meeting or exceeding clinically meaningful and normative values in bot...

Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

EULAR response by study visit (ITT population). Abbreviations: EULAR European League Against Rheumat...

Additional file 3: Figure S2. of Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Gerd Horneff (3415988)
Ariane Klein (3415976)
Jens Klotsche (93841)
Kirsten Minden (3415979)
Hans-Iko Huppertz (344746)
Frank Weller-Heinemann (3415991)
Jasmin Kuemmerle-Deschner (3415985)
Johannes-Peter Haas (2868563)
Anton Hospach (3415982)

November 2016

Drug survival during treatment with etanercept, adalimumab or tocilizumab (combined cohorts) dependi...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Abstract

Extracted data

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Abstract

Extracted data

Related items

Related items